Supplementary Table 2.
Associations of number of UPOINT domains in 1310 CP/CPPS patients treated at a single outpatient clinic from 1998–2014
| 1 | 2 | 3 | 4 | 5 | 6 | |
|---|---|---|---|---|---|---|
|
|
||||||
| n=249 | n=408 | n=368 | n=192 | n=39 | n=7 | |
| Age | 45.3 (±14.1) | 44.5 (±12.7) | 44.3 (±13.2) | 44.7 (±13.1) | 43.8 (±13.8) | 49.4 (±3.3) |
| CPSI pain | 9.2 (±4.6) | 10.6 (±4.6) | 11.1 (±4.9) | 11.6 (±5.2) | 11.8 (±4.3) | 14.3 (±2.8) |
| CPSI urination | 3.4 (±2.9) | 4.6 (±3.1) | 5.7 (±3.0) | 6.3 (±2.5) | 5.4 (±2.8) | 6.3 (±1.1) |
| CPSI QoL | 6.9 (±3.1) | 7.9 (±3.0) | 8.3 (±3.0) | 8.4 (±3.1) | 8.4 (±2.9) | 10.9 (±1.1) |
| CPSI total | 19.5 (±8.2) | 23.2 (±8.4) | 25.1 (±8.8) | 26.4 (±9.1) | 25.6 (±8.1) | 31.4 (±6.0) |
| UPOINT | ||||||
| U | 118 (47.4%) | 287 (70.3%) | 311 (84.5%) | 181 (94.3%) | 35 (89.7%) | 7 (100%) |
| P | 11 (4.4%) | 63 (15.4%) | 128 (34.8%) | 119 (62.0%) | 33 (84.6%) | 7 (100%) |
| O | 45 (18.1%) | 169 (41.4%) | 252 (68.5%) | 148 (77.1%) | 37 (94.9%) | 7 (100%) |
| I | 44 (17.7%) | 129 (31.6%) | 143 (38.9%) | 86 (44.8%) | 29 (74.4%) | 7 (100%) |
| N | 33 (13.3%) | 103 (25.2%) | 123 (33.4%) | 106 (55.2%) | 27 (69.2%) | 7 (100%) |
| T | 62 24.9%) | 160 (39.2%) | 227 (61.7%) | 153 (79.7%) | 34 (87.2%) | 7 (100%) |
| Pain locations | ||||||
| Perineum | 125 (50.2%) | 243 (59.6%) | 241 (65.5%) | 123 (64.1%) | 30 (76.9%) | 4 (57.1%) |
| Testicular | 108 (43.4) | 192 (47.1%) | 203 (55.2%) | 104 (54.2%) | 24 (61.5%) | 5 (71.4%) |
| Tip of penis | 74 (29.7%) | 146 (35.8%) | 128 (34.8%) | 65 (33.9%) | 16 (41.0%) | 1 (14.3%) |
| Pubic/bladder | 130 (52.2%) | 242 (59.3%) | 243 (66.0%) | 132 (68.8%) | 24 (61.5%) | 7 (100%) |
| Dysuria | 85 (34.1%) | 166 (40.7%) | 177 (48.1%) | 91 (47.4%) | 23 (59.0%) | 3 (42.9%) |
| Ejaculatory | 101 (40.6%) | 185 45.3%) | 187 (50.8%) | 106 (55.2%) | 18 (46.2%) | 4 (57.1%) |
| Treatment by referring physician* | ||||||
| Alpha-blockers | 128 (51.4%) | 236 (57.8%) | 265 (72.0%) | 125 (65.1%) | 30 (76.9%) | 6 (85.7%) |
| Antidepressants | 23 (9.2%) | 53 (13.0%) | 70 (19.0%) | 37 (19.3%) | 12 (30.8%) | 2 (28.6%) |
| Quercetin | 83 (33.3%) | 139 (34.1%) | 137 (37.2%) | 62 (32.3%) | 11 (28.2%) | 3 (42.9%) |
| QUrol | 18 (7.2%) | 33 (8.1%) | 38 (10.3%) | 18 (9.4%) | 5 (12.8%) | 0 (0%) |
| Gabapentinoids | 13 (5.2%) | 17 (4.2%) | 25 (6.8%) | 16 (8.3%) | 5 (12.8%) | 1 (14.3%) |
| Acupuncture | 1 (0.4%) | 2 (0.5%) | 3 (0.8%) | 3 (1.6%) | 1 (2.6%) | 0 (0%) |
| Physiotherapy | 6 (2.4%) | 8 (2.0%) | 9 (2.4%) | 7 (3.6%) | 1 (2.6%) | 0 (0%) |
| Antibiotics | 48 (19.3%) | 98 (24.0%) | 84 (22.8%) | 48 (25.0%) | 8 (20.5%) | 2 (28.6%) |
| Prostate massage | 8 (3.2%) | 19 (4.7%) | 10 (2.7%) | 5 (2.6%) | 1 (2.6%) | 0 (0%) |
*
Treatment provided by referring physician prior to or at time of evaluation of presentation to chronic prostatitis clinic.
CP/CPPS: chronic prostatitis/chronic pelvic pain syndrome; CPSI: chronic prostatitis symptom index; QoL: quality of life; UPOINT: urinary (U), psychosocial (P), organ-specific (O), infection (I), neurogenic (N), and tenderness (T).